499 related articles for article (PubMed ID: 20458050)
21. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
J Thorac Oncol; 2010 Aug; 5(8):1279-84. PubMed ID: 20559150
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
Scott BJ; Quant EC; McNamara MB; Ryg PA; Batchelor TT; Wen PY
Neuro Oncol; 2010 Jun; 12(6):603-7. PubMed ID: 20156808
[TBL] [Abstract][Full Text] [Related]
23. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Batchelor TT; Gerstner ER; Emblem KE; Duda DG; Kalpathy-Cramer J; Snuderl M; Ancukiewicz M; Polaskova P; Pinho MC; Jennings D; Plotkin SR; Chi AS; Eichler AF; Dietrich J; Hochberg FH; Lu-Emerson C; Iafrate AJ; Ivy SP; Rosen BR; Loeffler JS; Wen PY; Sorensen AG; Jain RK
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19059-64. PubMed ID: 24190997
[TBL] [Abstract][Full Text] [Related]
24. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
[TBL] [Abstract][Full Text] [Related]
26. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Batchelor TT; Sorensen AG; di Tomaso E; Zhang WT; Duda DG; Cohen KS; Kozak KR; Cahill DP; Chen PJ; Zhu M; Ancukiewicz M; Mrugala MM; Plotkin S; Drappatz J; Louis DN; Ivy P; Scadden DT; Benner T; Loeffler JS; Wen PY; Jain RK
Cancer Cell; 2007 Jan; 11(1):83-95. PubMed ID: 17222792
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
29. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
McWhirter E; Quirt I; Gajewski T; Pond G; Wang L; Hui J; Oza A
Invest New Drugs; 2016 Apr; 34(2):231-5. PubMed ID: 26841902
[TBL] [Abstract][Full Text] [Related]
32. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
di Tomaso E; Snuderl M; Kamoun WS; Duda DG; Auluck PK; Fazlollahi L; Andronesi OC; Frosch MP; Wen PY; Plotkin SR; Hedley-Whyte ET; Sorensen AG; Batchelor TT; Jain RK
Cancer Res; 2011 Jan; 71(1):19-28. PubMed ID: 21199795
[TBL] [Abstract][Full Text] [Related]
33. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
[TBL] [Abstract][Full Text] [Related]
38. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
[TBL] [Abstract][Full Text] [Related]
39. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
